In the United States biological-like drug "golden age" Pfizer, Amgen will make a big profit!

Read: Pfizer's global sales of biosimilars rose 36 percent to $289 million in the second quarter.
at Pfizer's second-quarter 2020 earnings conference call last week, analysts turned more attention to the company's potential future returns from research and development of the new generic vaccine, to the extent that biosimilars, which are currently the revenue business area, were overlooked.
Global sales of Pfizer biosimilars rose 36 percent to $289 million in the second quarter. In a note to investors earlier this week, Ronny Gal, an analyst at Bernstein, a top U.S. financial advisory firm, said Pfizer and Amgen were working together on a "golden age" for the U.S. biosimilar stake industry.

February 2020, Pfizer became the first u.S. company to sell three monoclonal antibody biosimilars, all of which are "discounted" versions of Roche's cancer-fighting star products, Zirabev, Ruxience and Trazimera (tretolmonotag).
discounts of 22-24% on these three drugs compared to the original drugs.
on a conference call, Albert Boura, Pfizer's chief executive, cited strong "early results" for the three products, particularly outside the U.S. market, where Trazimera's strong demand.
investors should not underestimate the potential of the U.S. biosimilar drug market.
to prove this, Gal analyzed data from Pfizer's biosimilar drug Inflectra, which has a 10 per cent share in the US market and 30 per cent in the price-sensitive European market.
Revenue spent in both the U.S. and Europe, with sales of $158 million in the U.S. and $116 million in Europe,
' higher prices in the U.S.
Gal forecasts annual sales of $2.1 billion in Pfizer's biosimilar selling business, which will eventually generate nearly $3 billion in annual revenue.
meanwhile, Amin's biosimilar stake business is on the rise, with Gal estimating revenue of $357 million in the second quarter and $1.4 billion on an annual basis.
amin dominates the U.S. biosimilar drug market, including Kanjinti, a Herceptin biosimilar drug in partnership with Aerling, which has a 32 percent commercial share, and Mvasi, a biosimilar drug for Avastin, which also has a 39 percent share.
Gal said Amin's re-entry of Remicade's biosimilars and the launch of Rituxan biosimilars later this year should bring the company's revenue in this area to $2 billion. "I think suppliers are looking for more markets so that biosimilars can be more valuable in the health care system, "
.
", says Gordon: "We have less challenge in share, but the entry of multiple competitors will make some changes to net prices." "Price pressures will not end the golden age of biosimilars any time soon, "
Gal admits.
discounts on the entire biosimilar drug system are increasing, there will be a transition to the drug model that should not come before the middle of the decade.
" Reference source: Pfizer, Amgen will rake in billions billions for biolikes: Analyst.